Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice

Lee Jia, Mark Garza, Hong Wong, Dody Reimer, Thomas Redelmeier, Jim B. Camden, Steven D Weitman

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Carbendazim is a novel anticancer agent. The aim of this study was to prepare and characterize a remote loaded liposome preparation of carbendazim, and compare its pharmacokinetic profile to that of unencapsulated carbendazim. Carbendazim was encapsulated in liposomes composed of sphingomyelin-cholesterol (3:1, w/w) by remote loading in response to a transmembrane pH gradient (pH 0.5 in/pH 4.0 out), which resulted in encapsulation of more than 95% of the available drug in preformed vesicles. High drug/lipid ratios were prepared which correspond to a molar ratio of up to 0.8. Physical isolation of the free drug and dialysis were used to determine the in vitro release of carbendazim from liposomes. The release was independent of the initial drug/lipid ratio and choice of internal buffer composition. Liposomal carbendazim (200 mg kg-1) was intravenously administered to athymic nude mice and the serum levels of free carbendazim were determined by HPLC analysis after a methanol-induced protein precipitation. Administration of liposomal carbendazim to mice resulted in significant alterations in the pharmacokinetics. Serum levels of free carbendazim were approximately 10-fold greater than those achieved for the same dose of unencapsulated drug. Liposomal carbendazim showed both high Cmax, AUC and low clearance rate. Liposomal carbendazim and unencapsulated carbendazim displayed a similar terminal half-life (43-48 min). The relatively large volume of distribution of carbendazim suggests that the compound may partially enter cells or be bound to some extravascular structures. The results indicate that the liposomal formulation of carbendazim significantly increases its blood concentrations.

Original languageEnglish (US)
Pages (from-to)65-72
Number of pages8
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume28
Issue number1
DOIs
StatePublished - Apr 1 2002

Fingerprint

Pharmacokinetics
Nude Mice
Liposomes
Pharmaceutical Preparations
carbendazim
Lipids
Proton-Motive Force
Dialysis
Sphingomyelins
Serum
Encapsulation
Antineoplastic Agents
Area Under Curve
Methanol
Half-Life

Keywords

  • Carbendazim
  • Liposomes
  • Pharmacokinetics
  • Remote loading

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmaceutical Science

Cite this

Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice. / Jia, Lee; Garza, Mark; Wong, Hong; Reimer, Dody; Redelmeier, Thomas; Camden, Jim B.; Weitman, Steven D.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 28, No. 1, 01.04.2002, p. 65-72.

Research output: Contribution to journalArticle

Jia, Lee ; Garza, Mark ; Wong, Hong ; Reimer, Dody ; Redelmeier, Thomas ; Camden, Jim B. ; Weitman, Steven D. / Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice. In: Journal of Pharmaceutical and Biomedical Analysis. 2002 ; Vol. 28, No. 1. pp. 65-72.
@article{2b3b917eedc242209f426d4d07d6013c,
title = "Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice",
abstract = "Carbendazim is a novel anticancer agent. The aim of this study was to prepare and characterize a remote loaded liposome preparation of carbendazim, and compare its pharmacokinetic profile to that of unencapsulated carbendazim. Carbendazim was encapsulated in liposomes composed of sphingomyelin-cholesterol (3:1, w/w) by remote loading in response to a transmembrane pH gradient (pH 0.5 in/pH 4.0 out), which resulted in encapsulation of more than 95{\%} of the available drug in preformed vesicles. High drug/lipid ratios were prepared which correspond to a molar ratio of up to 0.8. Physical isolation of the free drug and dialysis were used to determine the in vitro release of carbendazim from liposomes. The release was independent of the initial drug/lipid ratio and choice of internal buffer composition. Liposomal carbendazim (200 mg kg-1) was intravenously administered to athymic nude mice and the serum levels of free carbendazim were determined by HPLC analysis after a methanol-induced protein precipitation. Administration of liposomal carbendazim to mice resulted in significant alterations in the pharmacokinetics. Serum levels of free carbendazim were approximately 10-fold greater than those achieved for the same dose of unencapsulated drug. Liposomal carbendazim showed both high Cmax, AUC and low clearance rate. Liposomal carbendazim and unencapsulated carbendazim displayed a similar terminal half-life (43-48 min). The relatively large volume of distribution of carbendazim suggests that the compound may partially enter cells or be bound to some extravascular structures. The results indicate that the liposomal formulation of carbendazim significantly increases its blood concentrations.",
keywords = "Carbendazim, Liposomes, Pharmacokinetics, Remote loading",
author = "Lee Jia and Mark Garza and Hong Wong and Dody Reimer and Thomas Redelmeier and Camden, {Jim B.} and Weitman, {Steven D}",
year = "2002",
month = "4",
day = "1",
doi = "10.1016/S0731-7085(01)00702-6",
language = "English (US)",
volume = "28",
pages = "65--72",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice

AU - Jia, Lee

AU - Garza, Mark

AU - Wong, Hong

AU - Reimer, Dody

AU - Redelmeier, Thomas

AU - Camden, Jim B.

AU - Weitman, Steven D

PY - 2002/4/1

Y1 - 2002/4/1

N2 - Carbendazim is a novel anticancer agent. The aim of this study was to prepare and characterize a remote loaded liposome preparation of carbendazim, and compare its pharmacokinetic profile to that of unencapsulated carbendazim. Carbendazim was encapsulated in liposomes composed of sphingomyelin-cholesterol (3:1, w/w) by remote loading in response to a transmembrane pH gradient (pH 0.5 in/pH 4.0 out), which resulted in encapsulation of more than 95% of the available drug in preformed vesicles. High drug/lipid ratios were prepared which correspond to a molar ratio of up to 0.8. Physical isolation of the free drug and dialysis were used to determine the in vitro release of carbendazim from liposomes. The release was independent of the initial drug/lipid ratio and choice of internal buffer composition. Liposomal carbendazim (200 mg kg-1) was intravenously administered to athymic nude mice and the serum levels of free carbendazim were determined by HPLC analysis after a methanol-induced protein precipitation. Administration of liposomal carbendazim to mice resulted in significant alterations in the pharmacokinetics. Serum levels of free carbendazim were approximately 10-fold greater than those achieved for the same dose of unencapsulated drug. Liposomal carbendazim showed both high Cmax, AUC and low clearance rate. Liposomal carbendazim and unencapsulated carbendazim displayed a similar terminal half-life (43-48 min). The relatively large volume of distribution of carbendazim suggests that the compound may partially enter cells or be bound to some extravascular structures. The results indicate that the liposomal formulation of carbendazim significantly increases its blood concentrations.

AB - Carbendazim is a novel anticancer agent. The aim of this study was to prepare and characterize a remote loaded liposome preparation of carbendazim, and compare its pharmacokinetic profile to that of unencapsulated carbendazim. Carbendazim was encapsulated in liposomes composed of sphingomyelin-cholesterol (3:1, w/w) by remote loading in response to a transmembrane pH gradient (pH 0.5 in/pH 4.0 out), which resulted in encapsulation of more than 95% of the available drug in preformed vesicles. High drug/lipid ratios were prepared which correspond to a molar ratio of up to 0.8. Physical isolation of the free drug and dialysis were used to determine the in vitro release of carbendazim from liposomes. The release was independent of the initial drug/lipid ratio and choice of internal buffer composition. Liposomal carbendazim (200 mg kg-1) was intravenously administered to athymic nude mice and the serum levels of free carbendazim were determined by HPLC analysis after a methanol-induced protein precipitation. Administration of liposomal carbendazim to mice resulted in significant alterations in the pharmacokinetics. Serum levels of free carbendazim were approximately 10-fold greater than those achieved for the same dose of unencapsulated drug. Liposomal carbendazim showed both high Cmax, AUC and low clearance rate. Liposomal carbendazim and unencapsulated carbendazim displayed a similar terminal half-life (43-48 min). The relatively large volume of distribution of carbendazim suggests that the compound may partially enter cells or be bound to some extravascular structures. The results indicate that the liposomal formulation of carbendazim significantly increases its blood concentrations.

KW - Carbendazim

KW - Liposomes

KW - Pharmacokinetics

KW - Remote loading

UR - http://www.scopus.com/inward/record.url?scp=0036533206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036533206&partnerID=8YFLogxK

U2 - 10.1016/S0731-7085(01)00702-6

DO - 10.1016/S0731-7085(01)00702-6

M3 - Article

C2 - 11861109

AN - SCOPUS:0036533206

VL - 28

SP - 65

EP - 72

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

IS - 1

ER -